Robert Schooley, M.D., Joins Vertex Scientific Advisory Board

Robert Schooley, M.D., Joins Vertex Scientific Advisory Board
Page 2
Dr. Schooley has authored 135 publications in his field and serves on the editorial boards
of Antimicrobial Agents and Chemotherapy, Biotherapy and the Journal of Acquired
Immune Deficiency Syndromes. He is a member of the Governor's AIDS Council for the
State of Colorado.
Dr. Schooley holds a bachelor of science from Washington and Lee University and an
M.D. from The Johns Hopkins University School of Medicine.
Vertex is a leader in the use of structure-based rational drug design, a scientific approach
to drug discovery which uses atomic level information to design synthetic compounds
that interact with protein targets involved in disease processes. Vertex is using advanced
techniques of biology, chemistry and biophysics to create novel, small molecule
compounds that the Company plans to develop as orally deliverable drugs to treat major
human diseases. Vertex is concentrating on the development of drugs in the areas of
immunology, cancer, inflammation and antiviral therapy.